- Home
- NUS vs HQL Comparison
NUS vs HQL Comparison
Compare NUS & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- HQL
- Stock Information
- Founded
- NUS 1984
- HQL 1992
- Country
- NUS United States
- HQL United States
- Employees
- NUS N/A
- HQL N/A
- Industry
- NUS Other Pharmaceuticals
- HQL Investment Managers
- Sector
- NUS Health Care
- HQL Finance
- Exchange
- NUS Nasdaq
- HQL Nasdaq
- Market Cap
- NUS 353.9M
- HQL 372.7M
- IPO Year
- NUS 1996
- HQL N/A
- Fundamental
- Price
- NUS $6.82
- HQL $14.22
- Analyst Decision
- NUS Hold
- HQL
- Analyst Count
- NUS 2
- HQL 0
- Target Price
- NUS $6.88
- HQL N/A
- AVG Volume (30 Days)
- NUS 743.8K
- HQL 120.9K
- Earning Date
- NUS 02-13-2025
- HQL 01-01-0001
- Dividend Yield
- NUS 3.41%
- HQL 11.56%
- EPS Growth
- NUS N/A
- HQL N/A
- EPS
- NUS N/A
- HQL 0.79
- Revenue
- NUS $1,775,172,000.00
- HQL N/A
- Revenue This Year
- NUS N/A
- HQL N/A
- Revenue Next Year
- NUS N/A
- HQL N/A
- P/E Ratio
- NUS N/A
- HQL $17.08
- Revenue Growth
- NUS N/A
- HQL N/A
- 52 Week Low
- NUS $5.95
- HQL $11.34
- 52 Week High
- NUS $18.97
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- NUS 46.89
- HQL 64.15
- Support Level
- NUS $6.71
- HQL $14.01
- Resistance Level
- NUS $7.07
- HQL $14.27
- Average True Range (ATR)
- NUS 0.32
- HQL 0.20
- MACD
- NUS 0.00
- HQL 0.09
- Stochastic Oscillator
- NUS 44.12
- HQL 95.58
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.